Background: Cardiomyopathies are a heterogeneous group of pathologies characterized by
structural and functional alterations of the heart. Aims: The purpose of this narrative review is …

Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of
morbidity and mortality in the industrialized world. Modern treatment strategies have led to …

Purpose Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies
that can interfere with the efficacy of treatment, decrease quality of life, or impact the actual …

Background Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody–drug
conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and …

Heart failure is a common, costly, and debilitating syndrome that is associated with a highly
complex drug regimen, a large number of comorbidities, and a large and often disparate …

Long-term survival rates after a diagnosis of breast cancer are steadily rising. This is good
news, but clinicians must also recognize that this brings new challenges to the medical …

Background—Because cancer patients survive longer, the impact of cardiotoxicity
associated with the use of cancer treatments escalates. The present study investigates …

Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20–30% of
breast cancer tumors. It is associated with a more aggressive disease, higher recurrence …

Background Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody–drug
conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and …

Background Trastuzumab has established efficacy against breast cancer with
overexpression or amplification of the HER2 oncogene. The standard of care is 1 year of …